| Literature DB >> 30587939 |
Xingchu Meng1, Wei Gao1, Kai Wang1, Chao Han1, Wei Zhang1, Chao Sun1.
Abstract
PURPOSE: Adherence to the medical regimen after pediatric liver transplantation is crucial for good clinical outcomes. However, the existing literature provides inconsistent evidence regarding the prevalence of and risk factors for nonadherence to the medical regimen after pediatric liver transplantation. This study aimed to investigate such nonadherence after pediatric liver transplantation and risk factors associated with this nonadherence using findings of reported studies.Entities:
Keywords: compliance; hepar; hepatic; pediatrics; transplant
Year: 2018 PMID: 30587939 PMCID: PMC6301298 DOI: 10.2147/PPA.S181195
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Figure 1Meta-analysis article screening flowchart.
Characteristic of original studies
| First author | Year | Country | Sample age | Assessment of nonadherence | Patients (n) | Duration of observation (years) | Study design | NOS scores | |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Kennard | 1991 | USA | Children | Clinical record | 35 | 11 | 0.5 | Cohort | 5 |
| Debolt | 1995 | USA | Children and adolescent | Cyclosporine | 39 | 0 | 4 | Cohort | 5 |
| Sellers | 1997 | USA | Children and adolescent | Global | 57 | 11 | 3.7 | Cohort | 6 |
| Sudan | 1997 | USA | Children and adolescent | Global | 23 | 4 | 1 | Cohort | 7 |
| Molmenti | 1999 | USA | Children and adolescent | Cyclosporine | 28 | 11 | 9 | Cohort | 7 |
| Lurie | 2000 | USA | Children and adolescent | Global | 19 | 3 | 9 | Cohort | 7 |
| Avitzur | 2004 | Canada | Children and adolescent | Global | 32 | 2 | 1.5 | Cohort | 7 |
| Children and adolescent | Cyclosporine | 32 | 8 | 1.5 | Cohort | 7 | |||
| Berquist | 2006 | USA | Adolescent | Clinical record | 97 | 37 | 10 | Cohort | 7 |
| Adolescent | Cyclosporine | 27 | 14 | 10 | Cohort | 6 | |||
| Adolescent | Tacrolimus | 62 | 23 | 10 | Cohort | 7 | |||
| Annunziato | 2007 | USA | Adolescent | Global | 14 | 4 | 3 | Cohort | 7 |
| Bueno | 2007 | Spain | Children | Global | 50 | 5 | 3.3 | Cohort | 8 |
| Fredericks | 2007 | USA | Children | Clinical record | 38 | 19 | 10 | Cohort | 7 |
| Berquist | 2008 | USA | Adolescent | Clinical record | 111 | 50 | 5 | Cohort | 6 |
| Adolescent | Cyclosporine | 38 | 21 | 5 | Cohort | 7 | |||
| Adolescent | Tacrolimus | 73 | 29 | 5 | Cohort | 6 | |||
| Fredericks | 2008 | USA | Adolescent | Tacrolimus | 25 | 8 | 2 | Cohort | 7 |
| Shemesh | 2008 | USA | Children and adolescent | Tacrolimus | 23 | 6 | 1 | Cohort | 7 |
| Stuber | 2008 | USA | Children and adolescent | Tacrolimus | 68 | 26 | 2 | Cohort | 7 |
| Venkat | 2008 | USA | Children | Tacrolimus | 101 | 32 | 5.3 | Cohort | 8 |
| Miloh | 2009 | USA | Children and adolescent | Clinical record | 41 | 17 | 2 | Cohort | 7 |
| Fredericks | 2010 | USA | Children and adolescent | Clinical record | 71 | 40 | 9.41 | Cohort | 6 |
| Children and adolescent | Cyclosporine | 71 | 19 | 9.41 | Cohort | 7 | |||
| Children and adolescent | Tacrolimus | 71 | 22 | 9.41 | Cohort | 5 | |||
| Bilhartz | 2015 | USA | Adolescent | Tacrolimus | 48 | 16 | 12 | Cohort | 7 |
| Fredericks | 2015 | USA | Children and adolescent | Clinical record | 45 | 24 | 1 | Cohort | 7 |
| Bahador | 2015 | Iran | Children | Global | 112 | 21 | 5 | Cohort | 7 |
| Shemesh | 2018 | USA | Children and adolescent | Global | 222 | 41 | 10 | Cohort | 7 |
Abbreviation: NOS, Newcastle-Ottawa scale.
Figure 2Summary of meta-analysis regarding to different subgroups.
Note: Weights are from random effects analysis.
Abbreviation: ES, estimated statistics (transformed proportion).
Summary of nonadherence rate
| Nonadherence | Transformed proportion | Transformed 95% CI
| Estimated nonadherence rate (%) | 95% CI
| ||
|---|---|---|---|---|---|---|
| Lower | Higher | Lower (%) | Higher (%) | |||
|
| ||||||
| Clinical | 1.48 | 1.35 | 1.60 | 45 | 39 | 51 |
| Global | 0.84 | 0.74 | 0.94 | 17 | 13 | 21 |
| Cyclosporine | 1.34 | 1.08 | 1.61 | 39 | 26 | 52 |
| Tacrolimus | 1.25 | 1.16 | 1.34 | 34 | 30 | 39 |
Abbreviation: CI, confidence interval.
Summary of publication bias (P)
| Publication bias | Global | Clinical record | Tacrolimus | Cyclosporine | Overall |
|---|---|---|---|---|---|
|
| |||||
| Begg’s | 0.536 | 0.548 | 0.266 | 0.462 | 0.248 |
| Egger’s | 0.55 | 0.989 | 0.423 | 0.348 | 0.419 |
Outcome variables assessed in original articles
| Year | Sociodemographic characteristics
| Adverse effect
| Social psychological factors
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gender | Race | Age | Family income | Parent education | Health insurance | Rejection | Graft loss | Death | Single parent | Mental health | Parent cohesion | Social function | ||
|
| ||||||||||||||
| Kennard | 1991 | × | × | |||||||||||
| Sudan | 1997 | |||||||||||||
| Sellers | 1997 | × | ||||||||||||
| Molmenti | 1999 | |||||||||||||
| Avitzur | 2004 | |||||||||||||
| Berquist | 2006 | × | ||||||||||||
| Annunziato | 2007 | |||||||||||||
| Fredericks | 2007 | |||||||||||||
| Berquist | 2008 | × | × | |||||||||||
| Fredericks | 2008 | |||||||||||||
| Stuber | 2008 | |||||||||||||
| Venkat | 2008 | |||||||||||||
| Miloh | 2009 | × | ||||||||||||
| Fredericks | 2010 | × | ||||||||||||
| Bilhartz | 2015 | × | ||||||||||||
| Fredericks | 2015 | |||||||||||||
| Bahador | 2015 | |||||||||||||
| Shemesh | 2018 | |||||||||||||
Notes:
means significance from original articles of risk factors; × means no significant reports of risk factors. Blank cells indicate no relevant record in original articles.